CO4750675A1 - ENV-GLUCOPROTEIN VACCINE FOR PROTECTION AGAINST VLCTH-I AND VCLTH-II INFECTION - Google Patents
ENV-GLUCOPROTEIN VACCINE FOR PROTECTION AGAINST VLCTH-I AND VCLTH-II INFECTIONInfo
- Publication number
- CO4750675A1 CO4750675A1 CO97041595A CO97041595A CO4750675A1 CO 4750675 A1 CO4750675 A1 CO 4750675A1 CO 97041595 A CO97041595 A CO 97041595A CO 97041595 A CO97041595 A CO 97041595A CO 4750675 A1 CO4750675 A1 CO 4750675A1
- Authority
- CO
- Colombia
- Prior art keywords
- polypeptide
- htlv
- host cell
- infection
- vlcth
- Prior art date
Links
Abstract
Un polipéptido antigénico o inmunogénico que tiene unasecuencia amino ácida correspondiente a la proteína envolvente de HTLV-II suprimida de una porción suficiente del dominio de secuencia líder, de modo que el polipéptido, cuando es expresado por una célula anfitriona diseñada genéticamente, no queda anclado en la membrana de la célula anfitriona, o cualquier análogo de la misma, y un portador farmacéuticamente aceptable. Un polipéptido antigénico o inmunogénico que tiene una secuencia amino ácida correspondiente a la proteína envolvente de HTLV-I suprimida de una porción suficiente del dominio de secuencia líder, de modo que el polipéptido, cuando es expresado por una célula anfitriona diseñada genéticamente, no queda anclado en la membrana de la célula anfitriona, o un análogo de la misma, y un portador farmacéuticamente aceptable. Un método de tratamiento o prevención de una enfermedad o desorden en un sujeto, causado por una infección con HTLV-II que comprende administrar al sujeto el polipéptido de la Reivindicación 1 en una cantidad suficiente para proteger al sujeto contra el desafío con el virus de HTLV-II.An antigenic or immunogenic polypeptide having an amino acid sequence corresponding to the HTLV-II envelope protein deleted from a sufficient portion of the leader sequence domain, so that the polypeptide, when expressed by a genetically engineered host cell, is not anchored in the host cell membrane, or any analog thereof, and a pharmaceutically acceptable carrier. An antigenic or immunogenic polypeptide having an amino acid sequence corresponding to the HTLV-I envelope protein deleted from a sufficient portion of the leader sequence domain, so that the polypeptide, when expressed by a genetically engineered host cell, is not anchored on the host cell membrane, or an analog thereof, and a pharmaceutically acceptable carrier. A method of treating or preventing a disease or disorder in a subject caused by an HTLV-II infection comprising administering to the subject the polypeptide of Claim 1 in an amount sufficient to protect the subject against challenge with the HTLV virus -II.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68105496A | 1996-07-22 | 1996-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4750675A1 true CO4750675A1 (en) | 1999-03-31 |
Family
ID=24733624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97041595A CO4750675A1 (en) | 1996-07-22 | 1997-07-22 | ENV-GLUCOPROTEIN VACCINE FOR PROTECTION AGAINST VLCTH-I AND VCLTH-II INFECTION |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR003102A1 (en) |
| AU (1) | AU3807397A (en) |
| BR (1) | BR9711809A (en) |
| CO (1) | CO4750675A1 (en) |
| PE (1) | PE108098A1 (en) |
-
1997
- 1997-07-22 AU AU38073/97A patent/AU3807397A/en not_active Abandoned
- 1997-07-22 AR ARP970103292A patent/AR003102A1/en unknown
- 1997-07-22 PE PE00065397A patent/PE108098A1/en not_active Application Discontinuation
- 1997-07-22 CO CO97041595A patent/CO4750675A1/en unknown
- 1997-07-22 BR BR9711809-5A patent/BR9711809A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3807397A (en) | 1998-02-10 |
| BR9711809A (en) | 2001-11-06 |
| AR003102A1 (en) | 1998-07-08 |
| PE108098A1 (en) | 1999-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4951196A (en) | Vaccines for plague | |
| HUP9901186A2 (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
| DE69632235D1 (en) | Newcastle disease viral vaccines combined | |
| DK0835315T3 (en) | Vaccine for porcine reproductive and respiratory syndrome virus | |
| DE69529219T2 (en) | HELICOBACTER PROTEINS AND VACCINES | |
| ATE103982T1 (en) | RECOMBINANTLY MANUFACTURED BLOOD FACTORS, METHOD OF EXPRESSING SAID BLOOD FACTORS, AND RECOMBINANT VACCINA VIRUS USED IN SAID PROCESS. | |
| ES2104535T1 (en) | VACCINE CONTAINING EXTERNAL MEMBRANE PROTEIN OF BORDETELLA PERTUSSIS, AND METHOD FOR PREPARING SUCH A VACCINE. | |
| ATE355375T1 (en) | BACTERIOFERRITIN FROM HELICOBACTER PYLORI | |
| ATE79548T1 (en) | HERPES SIMPLEX VIRUS SUBUNITE VACCINE. | |
| TW377373B (en) | Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease | |
| BR0012433A (en) | Recombinant virus, infectious from infectious bursal disease, method to obtain the same, ibdv infectious mosaic (mibdv), and vaccine | |
| PT1015595E (en) | DERIVATIVE PEPTIDES OF LIGACAO (G) PROTEIN FROM RESPIRATORY SYNCYCIAL VIRUS | |
| HUP9904171A2 (en) | Immunogenic peptides of foot-and-mouth disease viruses | |
| KR970703428A (en) | FUSION GLYCOPROTEIN FROM HCMV AND HSV FROM HCMV AND HSV | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| CO4750675A1 (en) | ENV-GLUCOPROTEIN VACCINE FOR PROTECTION AGAINST VLCTH-I AND VCLTH-II INFECTION | |
| PT833903E (en) | Multivalent Bovine Coroanavirus Vaccine and Method for Treating Influenza Decoronaviruses of Bovine | |
| AR010794A1 (en) | VACCINE FOR IN OVO VACCINATION OF POULTRY AGAINST NEWCASTLE DISEASE AND USE OF NEWCASTLE DISEASE VIRUSES IN THE PREPARATION OF DICHAVACUNA | |
| DK0762895T3 (en) | Synthetic vaccine for protection against human immunodeficiency virus infection | |
| DK0563254T3 (en) | Use of IL-4 to enhance immune response to immunogens in vaccines | |
| DZ1550A1 (en) | A cell-free vaccine against the marek disease virus. | |
| IE891296L (en) | A synthetic vaccine against foot and mouth disease and a¹process for the preparation thereof | |
| MX9602256A (en) | Marek's disease vaccine. | |
| WO1995007987A3 (en) | Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor | |
| DK0871738T3 (en) | Recombinant viral pseudoparticles and their use as vaccines or antitumor drugs |